Establishment of a new representative model of human ovarian cancer in mice

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  Zhang, Jianjun ^a,b,c   Chen, Xinlian ^a,b,c   Shi, Gang ^b   Xie, Xiaoyan ^a,b,c   Liu, Hongqian ^a,b,c   Zhang, Xuemei ^a,b,c   Lai, Yi ^b   Zuo, Yan ^b   Chen, Zhong ^d   Liu, Shanling ^a,b,c   Wang, He ^a,b,c  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Animal model; CA125; Human; Intraperitoneal; Ovary carcinoma

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

ABDOMINAL DISTENSION; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; CANCER CELL; CASE REPORT; CONTROLLED STUDY; CYTOGENETICS; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INOCULATION; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SUPERNATANT;

EID: 84873258143     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-9     Document Type: Article

References (28)

1. Cancer statistics, 2010. Jemal A, Siegel R, Xu JQ, Ward E, CA-Cancer J Clin 2010 60 277 300 10.3322/caac.20073 20610543
2. Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. Deraco M, Baratti D, Laterza B, Balestra MR, Mingrone E, Macrì A, Virzì S, Puccio F, Ravenda PS, Kusamura S, Eur J Surg Oncol 2011 37 4 9 10.1016/j.ejso.2010.11.004 21112721
3. Characterization of Intraperitoneal, Orthotopic, and Metastatic Xenograft Models of Human Ovarian Cancer. Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC, Mol Ther 2004 10 1032 1042 10.1016/j.ymthe.2004.08.013 15564135 (Pubitemid 39625247)
4. A human ovarian carcinoma murine xenograft model useful for preclinical trials. Elkas JC, Baldwin RL, Pegram M, Tseng Y, Slamon D, Karlan BY, Gynecol Oncol 2002 87 200 206 10.1006/gyno.2002.6819 12477452 (Pubitemid 36044087)
5. Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. Verschraegen CF, Hu W, Du Y, Mendoza J, Early J, Deavers M, Freedman RS, Bast RC Jr, Kudelka AP, Kavanagh JJ, Giovanella BC, Clin Cancer Res 2003 9 845 852 12576458 (Pubitemid 36182623)
6. A highly reproducible xenograft model for human ovarian carcinoma and application of MRI and ultrasound in longitudinal follow-up. Sallinen H, Anttila M, Narvainen J, Ordén MR, Ropponen K, Kosma VM, Heinonen S, Yla-Herttuala S, Gynecol Oncol 2006 103 315 320 10.1016/j.ygyno.2006.03.030 16677689 (Pubitemid 44374703)
7. Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. Massazza G, Tomasoni A, Lucchini V, Allavena P, Erba E, Colombo N, Mantovani A, D'Incalci M, Mangioni G, Giavazzi R, Int J Cancer 1989 44 494 500 10.1002/ijc.2910440320 2777413 (Pubitemid 19229310)
8. Characterization of a xenograft model of human ovarian carcinoma which produces intraperitoneal carcinomatosis and metastases. Molpus KL, Koelliker D, Atkins L, Kato DT, Buczek-Thomas J, Fuller AF, Hasan T, Int J Cancer 1996 67 588 595 10.1002/(SICI)1097-0215(19960807)67:4<588::AID-IJC20>3.0.CO;2-2 8759621 (Pubitemid 26414518)
9. Dynamic progression of an intraperitoneal xenograft model of human ovarian cancer and its potential for preclinical trials. Lin XJ, Chen XC, Wang L, Wei YQ, Kan B, Wen YJ, He X, Zhao X, J Exp Clin Cancer Res 2007 26 467 474 18365540 (Pubitemid 351157862)
10. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Hamilton TC, Young RC, Louie KG, Behrens BC, McKoy WM, Grotzinger KR, Ozols RF, Cancer Res 1984 44 5286 5290 6333272 (Pubitemid 15204502)
11. The development of a novel immunotherapy model of human ovarian cancer in human PBL-severe combined immunodeficient (SCID) mice. Walker W, Gallagher G, Clin Exp Immunol 1995 101 494 501 7664496
12. Intraperitoneal xenografts of human epithelial ovarian cancer in nude mice. Ward BG, Wallace K, Shepherd JH, Balkwill FR, Cancer Res 1987 47 2662 2667 3567897 (Pubitemid 17083157)
13. Heterologous growth of human ovarian cancer: a new in vivo testing system. Davy M, Mossige J, Johannesson J, Acta Obstet Gynecol Scand 1977 56 55 59 402784 (Pubitemid 8031336)
14. Human ovarian tumor heterotransplanted to"Nude"mice. Kullander S, Rausing A, Trope C, Acta Obstet Gynecol Scand 1978 57 149 159 10.3109/00016347809155895 636856 (Pubitemid 8291981)
15. Transplantation of a human ovarian cystadenocarcinoma into severe combined immunodeficient (SCID) mice-formation of metastases without significant alteration of the tumor cell phenotype. Schumacher U, Adam E, Horny HP, Dietl J, Int J Exp Pathol 1996 77 219 227 8977374 (Pubitemid 26388972)
16. Immunophenotype of human ovarian malignancies (cystadenocarcinomata and mixed mullerian tumor) established in SCID mice. Schumacher U, Adam E, Dietl J, Horny HP, Exp Mol Pathol 1997 64 103 113 10.1006/exmp.1997.2213 9316588 (Pubitemid 27431484)
17. Pharmacokinetics and biodistribution of samarium-153-labelled OC125 antibody coupled to CITCDTPA in a xenograft model of ovarian cancer. Kraeber-Bodere F, Mishra A, Thedrez P, Faivre-Chauvet A, Bardies M, Imai S, Boterff J, Chatal JF, Eur J Nucl Med 1996 23 560 567 10.1007/BF00833392 8698062 (Pubitemid 26140586)
18. Biological and pharmacological characterisation of three models of humanhe ovarian carcinoma established in nude mice: use of the CA125 tumour marker to predict antitumour activity. Burbridge MF, Kraus-Berthier L, Naze M, Pierre A, Atassi G, Guilbaud N, Int J Oncol 1999 15 1155 1162 10568822
19. Immunohistochemical detection of P-glycoprotein in endometrial adenocarcinoma. Axiotis CA, Monteagudo C, Merino MJ, LaPorte N, Neumann RD, Am J Pathol 1991 138 799 806 1707232
20. A rapid banding technique for human chromosomes. Seabright M, Lancet 1971 298 971 972
21. Basement membrane status in undifferenciated carcinomas of the ovary. Kuwashima Y, Uehara T, Kurosumi M, Kishi K, Shiromizu K, Matsuzawa M, Takayama S, Immunohistochemical distribution of type IV collagen and laminin. Eur J Gynecol Oncol 1995 16 81 186
22. Activated matrix metalloproteinase-2-A potential marker of prognosis for epithelial ovarian cancer. Wu XH, Li HL, Kang L, Li L, Wang WP, Shan BE, Gynecol Oncol 2002 84 126 134 10.1006/gyno.2001.6477 11748988 (Pubitemid 34056478)
23. Proteolytic remodeling of extracellular matrix. Birkedal-Hansen H, Curr Opin Cell Biol 1995 7 728 735 10.1016/0955-0674(95)80116-2 8573349
24. BAG3 (BCL2-associated athanogene 3) interacts with MMP-2 to positively regulate invasion by ovarian carcinoma cells. Suzuki M, Iwasaki M, Sugio A, Hishiya A, Tanaka R, Endo T, Takayama S, Saito T, Cancer Lett 2011 303 65 71 10.1016/j.canlet.2011.01.019 21316839
25. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Leitao MM, Soslow TA, Baergen RN, Olvera N, Arroyo C, Boyd J, Gynecol Oncol 2004 93 301 306 10.1016/j.ygyno.2004.01.043 15099937 (Pubitemid 38507593)
26. P53 gene mutation and protein accumulation in human ovarian cancer. Kupryjanczyk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA, Yandell DW, Proc Natl Acad Sci USA 1993 90 4961 4965 10.1073/pnas.90.11.4961 8506342 (Pubitemid 23182955)
27. P53 mutations and expression in ovarian cancers: collelation with overall survival. Wen WH, Reles A, Runnebaum IB, Sullivan-Halley J, Bernstein L, Jones LA, Felix JC, Kreienberg R, El-Naggar A, Press MF, Int J Gynecol Pathol 1999 18 29 31 10.1097/00004347-199901000-00005 9891239
28. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Chan WY, Cheung KK, Schorge JO, Huang LW, Welch WR, Bell DA, Berkowitz RS, Mok SC, Am J Pathol 2000 156 409 417 10.1016/S0002- 9440(10)64744-X 10666369 (Pubitemid 30643795)